Search | Clinical Trials Finder

Conditions: Appetitive Behavior
Interventions: High protein ramen, Standard ramen; Other
Lead sponsor: Texas Tech University; Other
Eligibility: 25 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Type 1 Diabetes Mellitus
Interventions: Insulin, Pramlintide + Insulin; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 12 Years to 21 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Multiple Myeloma
Interventions: Vactosertib, Pomalidomide; Drug
Lead sponsor: Koen van Besien; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 2 Diabetes
Interventions: Long-acting bedtime insulin detemir (Levemir), Insulin detemir and pre-meal insulin aspart.; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec/liraglutide, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Fresno, California • Fort Lauderdale, Florida • Gurnee, Illinois + 4 more

Conditions: Urea Cycle Disorders
Interventions: HPN-100; Drug
Lead sponsor: Amgen; Industry
Eligibility: 1 Year and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 15
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 12 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin glargine, 75% insulin lispro protamine suspension and 25 % insulin lispro injection; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Rheumatoid Arthritis (RA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions: Ketogenic diet, Carnivore (Lion) Diet; Behavioral
Lead sponsor: Fuller Research Foundation; Other
Eligibility: 18 Years to 64 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Obesity
Interventions: Dietary counseling; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 12 Years to 17 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight
Interventions: Dietary Supplements and TR90 Eating Plan, Placebo and Low Fat Eating Plan; Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 141 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin aspart, liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 48
States / cities: Concord, California • La Jolla, California • Lancaster, California + 44 more

Conditions: PreDiabetes, Type 2 Diabetes, Healthy
Interventions: Time Restrictive Eating- late, Time Restrictive Eating- early, Time Restrictive Eating- early with early caloric intake, Macronutrient-controlled meals; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 2 Diabetes Mellitus
Interventions: Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV; Drug
Lead sponsor: Carl T. Hayden VA Medical Center; Federal
Eligibility: 35 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Obese Patients (BMI ≥ 30 kg/m²), Glucose Metabolism, Protein Metabolism
Interventions: Indispensable Amino Acid Oxidation, Stable Isotope Oral Glucose Tolerance Test; Procedure
Lead sponsor: University of Illinois at Urbana-Champaign; Other
Eligibility: 19 Years to 59 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Urbana, Illinois

Conditions: Type 1 Diabetes
Interventions: Pramlintide, Glargine, Lispro, Aspart; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 12 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Interventions: Zumsemetinib, Capecitabine, Zoledronic acid, Denosumab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 3
States / cities: Westwood, Kansas • Rochester, Minnesota • St Louis, Missouri

Conditions: Weight Reduction, Obesity, Weight Management
Interventions: Herbalife Meal Replacements; Dietary Supplement
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 30 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Afrezza, Rapid-acting Insulin Analog, Basal Insulin; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 4 Years to 17 Years
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 39
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 35 more

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Adenocarcinoma
Interventions: Paclitaxel, Carboplatin, Bevacizumab, Metformin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Diabetic Foot Ulcer
Interventions: glucose control nutritional shake, nutrition education; Dietary Supplement
Lead sponsor: Florida State University; Other
Eligibility: 30 Years to 70 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Refractory Metastatic Colorectal Cancer
Interventions: Trifluridine/Tipiracil, Bevacizumab; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 12
States / cities: Phoenix, Arizona • Duarte, California • South Pasadena, California + 9 more

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Healthy
Interventions: Fasting, non fasting; Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Search by objective public record fields.

Satiety of High-Protein Ramen Noodles

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

Vactosertib in Combination w/ Pomalidomide in Relapsed or Relapsed and Refractory Multiple Myeloma

Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes

A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification

To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)

Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

Think AHEAD (A Healthy Eating And Drinking) Study

A Prospective Study Investigating the Effects of a Novel Weight Management Program

Comparison of the Efficacy and Safety of Two Intensification Strategies in Subjects With Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin

Effect of Meal Composition and Timing Modification on Glucose Metabolism, Body Temperature and Sleep

The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes

Stable Isotopes- Adults With Obesity

Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Effects of Protein-Enriched Meal on Liver, Kidney or Bone: a Randomized Controlled Trial

Afrezza® INHALE-1 Study in Pediatrics

Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

The Effects of Nutrition Supplementation and Education on the Healing of Diabetic Foot Ulcer (DFU)

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Intermittent Fasting on Body Fat and Quality of Life